MX2016000243A - Profarmacos de formacion de compuestos. - Google Patents

Profarmacos de formacion de compuestos.

Info

Publication number
MX2016000243A
MX2016000243A MX2016000243A MX2016000243A MX2016000243A MX 2016000243 A MX2016000243 A MX 2016000243A MX 2016000243 A MX2016000243 A MX 2016000243A MX 2016000243 A MX2016000243 A MX 2016000243A MX 2016000243 A MX2016000243 A MX 2016000243A
Authority
MX
Mexico
Prior art keywords
pro
forming compounds
drug forming
compounds
general structure
Prior art date
Application number
MX2016000243A
Other languages
English (en)
Other versions
MX364743B (es
Inventor
Walter Elger
Klaus Nickisch
Wyrwa Ralf
Santhamma Bindu
Ahmed Gulzar
Meece Frederick
Nair Hareesh
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52277568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of MX2016000243A publication Critical patent/MX2016000243A/es
Publication of MX364743B publication Critical patent/MX364743B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Varios compuestos de profármaco que tienen la estructura general: agente activo-(ácido)-(enlazador)-SO2NR1R2 se describen en este documento. Los compuestos con esta estructura general mostraron ser más oralmente activos que la molécula de origen sin modificar.
MX2016000243A 2013-07-11 2014-07-11 Profármacos de formación de compuestos. MX364743B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361844985P 2013-07-11 2013-07-11
PCT/US2014/046353 WO2015006691A1 (en) 2013-07-11 2014-07-11 Pro-drug forming compounds

Publications (2)

Publication Number Publication Date
MX2016000243A true MX2016000243A (es) 2017-03-03
MX364743B MX364743B (es) 2019-05-06

Family

ID=52277568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000243A MX364743B (es) 2013-07-11 2014-07-11 Profármacos de formación de compuestos.

Country Status (12)

Country Link
US (2) US9745338B2 (es)
EP (1) EP3019172B1 (es)
JP (1) JP6449274B2 (es)
CN (1) CN105636592A (es)
AU (1) AU2014287049B2 (es)
CL (1) CL2015003787A1 (es)
IL (1) IL243385B (es)
MX (1) MX364743B (es)
PE (1) PE20160655A1 (es)
RU (1) RU2667942C2 (es)
WO (1) WO2015006691A1 (es)
ZA (1) ZA201600766B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302368D0 (en) * 2013-02-11 2013-03-27 Univ Bath Compound
US9745338B2 (en) * 2013-07-11 2017-08-29 Evestra, Inc. Pro-drug forming compounds
US10053485B2 (en) * 2015-03-23 2018-08-21 Evestra, Inc. Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
CN108084075A (zh) * 2016-11-21 2018-05-29 天津大学 具有β-内酰胺酶抑制作用的脯氨酸衍生物
BR112020007673A2 (pt) * 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
CN110862400A (zh) * 2018-08-27 2020-03-06 遵义医学院 喜树碱-羟基乙酸中间体的制备工艺

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461118A (en) * 1966-10-17 1969-08-12 Syntex Corp 3beta-tetrahydrofuranyloxy - and 3beta-tetrahydropyranyloxyestra - 4,9(10) - dienes and -4,9(10),11-trienes,their preparation and intermediates thereof
JPS52148093A (en) * 1976-06-03 1977-12-08 Fujisawa Pharmaceut Co Ltd 7-(n-substituted-2-phenyl-glycineamido) cephalosporanic acid derivatives
US4260736A (en) * 1978-08-14 1981-04-07 Kureha Kagaku Kogyo Kabushiki Kaisha Steroid hormone-antitumor derivatives
US4615835A (en) 1983-11-17 1986-10-07 Stiftung Deutsches Krebsforschungs Zentrum Steroid esters of N-(2-halogenethyl)-N-nitroso-carbamoylamino and acids and peptides therefore, as well as method for preparing them
SE8802402D0 (sv) 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
DE4029499A1 (de) 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447714C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
US5705495A (en) 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
FR2774989B1 (fr) 1998-02-18 2000-03-17 Adir Nouveaux cytotoxiques derives de l'oestradiol
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US20050277625A1 (en) 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
ES2614090T3 (es) * 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2008113851A2 (en) * 2007-03-22 2008-09-25 Solvay Pharmaceuticals Gmbh Novel c11 modified retrosteroids as progesterone receptor modulator compounds
CN101801925A (zh) * 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
JP5509104B2 (ja) * 2008-03-14 2014-06-04 エグゼリクシス， インコーポレイテッド １１β−ＨＳＤ１モジュレータとしてのアザビシクロ［３．２．１］オクチル誘導体
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
KR101857467B1 (ko) 2009-12-14 2018-06-28 롬 앤드 하스 일렉트로닉 머트어리얼즈 엘엘씨 설포닐 광산 발생제 및 이를 포함하는 포토레지스트
CN102127137A (zh) 2010-12-10 2011-07-20 郑州大学 制备雌甾氨基酸酯的中间体化合物及其合成方法
CN102079771B (zh) 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
US9745338B2 (en) * 2013-07-11 2017-08-29 Evestra, Inc. Pro-drug forming compounds
US10053485B2 (en) * 2015-03-23 2018-08-21 Evestra, Inc. Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Also Published As

Publication number Publication date
MX364743B (es) 2019-05-06
AU2014287049B2 (en) 2019-09-26
PE20160655A1 (es) 2016-07-08
AU2014287049A1 (en) 2016-02-18
CL2015003787A1 (es) 2016-08-12
RU2016102182A3 (es) 2018-04-02
WO2015006691A1 (en) 2015-01-15
EP3019172B1 (en) 2019-09-25
US20150018322A1 (en) 2015-01-15
RU2667942C2 (ru) 2018-09-27
IL243385B (en) 2019-08-29
RU2016102182A (ru) 2017-08-16
EP3019172A1 (en) 2016-05-18
JP2016525101A (ja) 2016-08-22
CN105636592A (zh) 2016-06-01
JP6449274B2 (ja) 2019-01-09
EP3019172A4 (en) 2017-03-29
US9745338B2 (en) 2017-08-29
US20170349624A1 (en) 2017-12-07
IL243385A0 (en) 2016-02-29
ZA201600766B (en) 2017-03-29
US10273263B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
MX364743B (es) Profármacos de formación de compuestos.
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
EA201590321A1 (ru) Дейтерированный барицитиниб
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
EP3047030A4 (en) A high yield route for the production of compounds from renewable sources
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
UA113643C2 (xx) N-цикліламіди як нематоциди
IN2015DN00598A (es)
WO2014153188A3 (en) High efficiency, small volume nucleic acid synthesis
AR095097A1 (es) Compuestos de fenoxietoxi
EP3041476A4 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
EP2968147A4 (en) Acid stable liposomal compositions
NZ720106A (en) A process for the preparation of regadenoson
PT3090042T (pt) Estirpes de leveduras para a produção de etanol de primeira geração
EP2867990B8 (de) Quasi-breitbandiger verstärker nach dem doherty-prinzip
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EP3052530A4 (en) Amphiphilic cyclodextrin-based glycodendrimers
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
IN2013CH04314A (es)
IN2013MU01219A (es)
WO2014147464A3 (en) Novel process for the preparation of tolcapone
EP2989116A4 (en) Reduction of endotoxins from polyanionic polymer conjugates
IN2013MU02748A (es)

Legal Events

Date Code Title Description
FG Grant or registration